HD Labs R3t@trutide 32mg research peptide pen
HD Labs R3t@trutide 32mg peptide pen product view
HD Labs R3t@trutide 32mg research peptide packaging
Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

HD Labs R3t@trutide 32mg Research Peptide Pen

R 2,650.00
Add to WishlistCompare

HD Labs R3t@trutide 32mg Research Peptide Pen

HD Labs R3t@trutide 32mg is a research-focused peptide product supplied in a convenient pen format. The product contains 32mg of R3t@trutide (LY3437943) and is intended for laboratory and scientific research applications.

R3t@trutide is an investigational peptide that has attracted significant scientific interest because of its activity across multiple metabolic pathways. Research into R3t@trutide has examined its interaction with GLP-1, GIP and glucagon receptors, making it a subject of ongoing metabolic and peptide research.

Product Specifications

  • Product: HD Labs R3t@trutide

  • Total peptide: 32mg

  • Peptide: R3t@trutide

  • Research identifier: LY3437943

  • Format: Multi-use peptide pen

  • Brand: HD Labs

  • Application: Laboratory and scientific research

Research Overview

R3t@trutide (LY3437943) is being investigated as a multi-pathway metabolic peptide. Scientific research has focused on its activity at the:

  • GLP-1 receptor

  • GIP receptor

  • Glucagon receptor

This triple-pathway activity is one of the characteristics that has generated interest in R3t@trutide research.

Researchers have investigated R3t@trutide in areas including metabolic signalling, energy regulation, glucose homeostasis, lipid metabolism and body-weight-related research.

The HD Labs 32mg pen provides a clearly specified research formulation in a practical delivery format for laboratory protocols where product consistency and convenient handling are important.

Research & Protocol Notes

This product is supplied for research purposes. Researchers should establish handling, storage, analytical and experimental procedures according to their own laboratory requirements and applicable guidelines.

For research use only. Not intended for human or veterinary use.

Key Features
  • 32mg Pre-Filled Research Pen

  • Triple receptor agonist (GLP-1, GIP & Glucagon)

  • Investigational next-generation metabolic peptide

  • Precision pre-filled pen presentation

  • Designed for laboratory and scientific research

  • No peptide reconstitution required

  • Individually packaged for product integrity

  • Suitable for metabolic and obesity-related research models

  • Manufactured for research applications

  • Refrigerated storage recommended according to manufacturer guidance
Dosage & Usage

Compound: Retatrutide (LY3437943)

Presentation: 32mg Pre-Filled Research Pen

Research Classification


  • Triple GLP-1/GIP/Glucagon Receptor Agonist

  • Long-acting investigational peptide

  • Metabolic research compound

Research Focus

Retatrutide is currently being investigated in laboratory and clinical research involving:


  • Metabolic regulation

  • Obesity research

  • Appetite signalling

  • Glucose homeostasis

  • Energy expenditure

  • Cardiometabolic health

  • Body weight regulation

Clinical Trial Overview

Published clinical trials have evaluated Retatrutide using once-weekly administration with gradual dose escalation to improve tolerability before reaching assigned maintenance-dose groups. Different studies have investigated multiple maintenance-dose levels rather than a single standard regimen. Retatrutide remains an investigational compound and has not been approved for routine clinical use.

Storage


  • Store refrigerated according to the manufacturer's recommendations.

  • Protect from excessive heat and direct sunlight.

  • Keep in the original packaging until required for research handling.

  • Do not freeze unless specified by the manufacturer.
FAQ's & Tips

Frequently Asked Questions

What is Retatrutide?

Retatrutide is an investigational triple receptor agonist currently being studied for obesity, metabolic disease, and related cardiometabolic conditions.

What makes Retatrutide different?

Unlike traditional GLP-1 receptor agonists, Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously.

Why is it called a triple agonist?

Because one molecule activates three different hormone receptors involved in metabolic regulation.

Is this supplied as a vial?

No.

This product is supplied as a 32mg pre-filled research pen.

Is reconstitution required?

No.

The product is supplied in a ready-to-use pre-filled pen presentation.

What research areas is it commonly associated with?

Current scientific research includes:


  • Metabolic disease

  • Weight management

  • Appetite regulation

  • Energy expenditure

  • Glucose regulation

  • Cardiometabolic health

Is Retatrutide FDA approved?

No.

Retatrutide remains an investigational compound in Phase 3 clinical development and has not yet received FDA approval for routine clinical use.

How should the pen be stored?

Store refrigerated according to the manufacturer's recommendations.

Is this intended for laboratory research?

Yes.

The product is intended for scientific and laboratory research applications.

Why are researchers interested in Retatrutide?

Its triple receptor mechanism represents a next-generation approach to investigating metabolic regulation, with ongoing studies evaluating its potential across obesity and related metabolic disorders.

Research

Compound: Retatrutide

Presentation: 32mg Pre-Filled Research Pen

Research Classification


  • Triple Agonist

  • GLP-1 Receptor Agonist

  • GIP Receptor Agonist

  • Glucagon Receptor Agonist

Research Areas


  • Metabolic regulation

  • Obesity research

  • Appetite signalling

  • Energy expenditure

  • Insulin sensitivity

  • Glucose metabolism

  • Cardiometabolic research

Clinical studies have generally evaluated Retatrutide as a once-weekly investigational treatment with gradual dose escalation under controlled trial protocols. The specific regimens varied between studies, and there is no approved dosing protocol, as Retatrutide remains under clinical investigation and has not received regulatory approval for routine clinical use.

Reviews